Epoetin alfa in patients not on chemotherapy - Canadian data

Ian Quirt, Christine Robeson, Cathy Y. Lau, Michael Kovacs, Susan Burdette-Radoux, Sean Dolan, Shou-Ching Tang, Michael McKenzie, Felix Couture

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A prospective open-label study was designed to evaluate the safety, efficacy, and impact on quality of life of recombinant human erythropoietin (rHuEPO, epoetin alfa) therapy for cancer-related anemia. Of the 401 patients enrolled at 34 centers from across Canada, a cohort of 183 patients did not receive chemotherapy during the 16-week study period. All patients received epoetin alfa 150 IU/kg subcutaneously 3 times per week. The dose was increased to 300 IU/kg if the hemoglobin level did not increase by at least 1.0 g/dL after 4 weeks. Epoetin alfa therapy significantly increased hemoglobin levels and reduced transfusion requirements. Moreover, epoetin alfa provided statistically significant and clinically meaningful improvements in quality of life as measured by the Functional Assessment of Cancer Therapy-Anemia and Linear Analog Scale Assessment (also known as Cancer Linear Analog Scale). Increases in hemoglobin were correlated significantly with improvements in quality of life as well as Eastern Cooperative Oncology Group performance status. Treatment with epoetin alfa was well tolerated. These results demonstrate that epoetin alfa therapy is effective and safe in cancer patients with anemia, regardless of whether they are or are not receiving chemotherapy.

Original languageEnglish (US)
Pages (from-to)75-80
Number of pages6
JournalSeminars in Oncology
Volume29
Issue number3 SUPPL. 8
StatePublished - Jan 1 2002

Fingerprint

Epoetin Alfa
Drug Therapy
Anemia
Hemoglobins
Quality of Life
Neoplasms
Second Primary Neoplasms
Therapeutics
Erythropoietin
Canada

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Quirt, I., Robeson, C., Lau, C. Y., Kovacs, M., Burdette-Radoux, S., Dolan, S., ... Couture, F. (2002). Epoetin alfa in patients not on chemotherapy - Canadian data. Seminars in Oncology, 29(3 SUPPL. 8), 75-80.

Epoetin alfa in patients not on chemotherapy - Canadian data. / Quirt, Ian; Robeson, Christine; Lau, Cathy Y.; Kovacs, Michael; Burdette-Radoux, Susan; Dolan, Sean; Tang, Shou-Ching; McKenzie, Michael; Couture, Felix.

In: Seminars in Oncology, Vol. 29, No. 3 SUPPL. 8, 01.01.2002, p. 75-80.

Research output: Contribution to journalArticle

Quirt, I, Robeson, C, Lau, CY, Kovacs, M, Burdette-Radoux, S, Dolan, S, Tang, S-C, McKenzie, M & Couture, F 2002, 'Epoetin alfa in patients not on chemotherapy - Canadian data', Seminars in Oncology, vol. 29, no. 3 SUPPL. 8, pp. 75-80.
Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S et al. Epoetin alfa in patients not on chemotherapy - Canadian data. Seminars in Oncology. 2002 Jan 1;29(3 SUPPL. 8):75-80.
Quirt, Ian ; Robeson, Christine ; Lau, Cathy Y. ; Kovacs, Michael ; Burdette-Radoux, Susan ; Dolan, Sean ; Tang, Shou-Ching ; McKenzie, Michael ; Couture, Felix. / Epoetin alfa in patients not on chemotherapy - Canadian data. In: Seminars in Oncology. 2002 ; Vol. 29, No. 3 SUPPL. 8. pp. 75-80.
@article{7cd9d061132648949cbd6b97e88c86c1,
title = "Epoetin alfa in patients not on chemotherapy - Canadian data",
abstract = "A prospective open-label study was designed to evaluate the safety, efficacy, and impact on quality of life of recombinant human erythropoietin (rHuEPO, epoetin alfa) therapy for cancer-related anemia. Of the 401 patients enrolled at 34 centers from across Canada, a cohort of 183 patients did not receive chemotherapy during the 16-week study period. All patients received epoetin alfa 150 IU/kg subcutaneously 3 times per week. The dose was increased to 300 IU/kg if the hemoglobin level did not increase by at least 1.0 g/dL after 4 weeks. Epoetin alfa therapy significantly increased hemoglobin levels and reduced transfusion requirements. Moreover, epoetin alfa provided statistically significant and clinically meaningful improvements in quality of life as measured by the Functional Assessment of Cancer Therapy-Anemia and Linear Analog Scale Assessment (also known as Cancer Linear Analog Scale). Increases in hemoglobin were correlated significantly with improvements in quality of life as well as Eastern Cooperative Oncology Group performance status. Treatment with epoetin alfa was well tolerated. These results demonstrate that epoetin alfa therapy is effective and safe in cancer patients with anemia, regardless of whether they are or are not receiving chemotherapy.",
author = "Ian Quirt and Christine Robeson and Lau, {Cathy Y.} and Michael Kovacs and Susan Burdette-Radoux and Sean Dolan and Shou-Ching Tang and Michael McKenzie and Felix Couture",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "29",
pages = "75--80",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 8",

}

TY - JOUR

T1 - Epoetin alfa in patients not on chemotherapy - Canadian data

AU - Quirt, Ian

AU - Robeson, Christine

AU - Lau, Cathy Y.

AU - Kovacs, Michael

AU - Burdette-Radoux, Susan

AU - Dolan, Sean

AU - Tang, Shou-Ching

AU - McKenzie, Michael

AU - Couture, Felix

PY - 2002/1/1

Y1 - 2002/1/1

N2 - A prospective open-label study was designed to evaluate the safety, efficacy, and impact on quality of life of recombinant human erythropoietin (rHuEPO, epoetin alfa) therapy for cancer-related anemia. Of the 401 patients enrolled at 34 centers from across Canada, a cohort of 183 patients did not receive chemotherapy during the 16-week study period. All patients received epoetin alfa 150 IU/kg subcutaneously 3 times per week. The dose was increased to 300 IU/kg if the hemoglobin level did not increase by at least 1.0 g/dL after 4 weeks. Epoetin alfa therapy significantly increased hemoglobin levels and reduced transfusion requirements. Moreover, epoetin alfa provided statistically significant and clinically meaningful improvements in quality of life as measured by the Functional Assessment of Cancer Therapy-Anemia and Linear Analog Scale Assessment (also known as Cancer Linear Analog Scale). Increases in hemoglobin were correlated significantly with improvements in quality of life as well as Eastern Cooperative Oncology Group performance status. Treatment with epoetin alfa was well tolerated. These results demonstrate that epoetin alfa therapy is effective and safe in cancer patients with anemia, regardless of whether they are or are not receiving chemotherapy.

AB - A prospective open-label study was designed to evaluate the safety, efficacy, and impact on quality of life of recombinant human erythropoietin (rHuEPO, epoetin alfa) therapy for cancer-related anemia. Of the 401 patients enrolled at 34 centers from across Canada, a cohort of 183 patients did not receive chemotherapy during the 16-week study period. All patients received epoetin alfa 150 IU/kg subcutaneously 3 times per week. The dose was increased to 300 IU/kg if the hemoglobin level did not increase by at least 1.0 g/dL after 4 weeks. Epoetin alfa therapy significantly increased hemoglobin levels and reduced transfusion requirements. Moreover, epoetin alfa provided statistically significant and clinically meaningful improvements in quality of life as measured by the Functional Assessment of Cancer Therapy-Anemia and Linear Analog Scale Assessment (also known as Cancer Linear Analog Scale). Increases in hemoglobin were correlated significantly with improvements in quality of life as well as Eastern Cooperative Oncology Group performance status. Treatment with epoetin alfa was well tolerated. These results demonstrate that epoetin alfa therapy is effective and safe in cancer patients with anemia, regardless of whether they are or are not receiving chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0036288097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036288097&partnerID=8YFLogxK

M3 - Article

C2 - 12082658

AN - SCOPUS:0036288097

VL - 29

SP - 75

EP - 80

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 8

ER -